Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Analog Devices, Inc. (ADI) Price & Performance

Abbott LaboratoriesTrade
Analog Devices, Inc.Trade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Analog Devices, Inc. — how do they compare? Abbott Laboratories trades at $108.81 (market cap $187.95B), while Analog Devices, Inc. trades at $390.08 (market cap $187.67B). The key difference: Abbott Laboratories and Analog Devices, Inc. are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTADI
Market Cap
$187.95B$187.67B
Sector
HealthTechnology
52-Week High
$136.62$445.48
52-Week Low
$82.57$225.20
Enterprise Value
$214.96B$192.92B
Dividend Yield
2.32%1.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Analog Devices, Inc.

Analog Devices (ADI) trades at $383.93, down 1.54% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 26.01% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights institutional buying and a spin-off of ADI Global Distribution, completed August 4, 2026, as per a Business Wire report.

The outlook is positive, supported by a strong analyst consensus with a $472.29 price target and no sell ratings. Key opportunities include consistent earnings outperformance and exposure to semiconductor sector growth. Risks involve high valuation multiples and potential market volatility impacting the stock's premium pricing.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Analog Devices, Inc.

Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.

Read more on ADI